Search results for " Tolerability"

showing 10 items of 11 documents

Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohor…

2019

Abstract Background Study aim was to evaluate the safety and durability of darunavir/cobicistat (DRV/c) in a real life setting. Methods Multicentre prospective cohort study performed in the context of SCOLTA (Surveillance Cohort Long-Term Toxicity Antiretrovirals). Patients were evaluated at baseline, week 24 and 48. Changes were evaluated using the paired t test or signed rank test. The multivariable analysis was performed using a general linear model, after ranking of not normally distributed variables. Results A total of 249 patients were included, 72 (29%) were in DRV/c-based dual therapies (DT). Hypercholesterolemia, HC, (total cholesterol (TC) ≥ 200 mg/dL or low density-C (LDL-C) ≥ 13…

0301 basic medicineMaleHIV Infections0302 clinical medicineDualMedicineHIV InfectionPharmacology (medical)030212 general & internal medicineProspective StudiesProspective cohort studyDarunavirCobicistatMiddle AgedViral LoadTolerabilityTolerabilityAnti-Retroviral AgentsCohortMolecular MedicineDrug Therapy CombinationFemaleDarunavir/cobicistatHumanmedicine.drugAdverse eventAdultlcsh:Immunologic diseases. Allergymedicine.medical_specialty030106 microbiologyContext (language use)Durability03 medical and health sciencesDarunavir/cobicistat Dual Durability Tolerability CISAI Adverse eventsVirologyInternal medicineHumansDarunavirbusiness.industryResearchHypertriglyceridemiamedicine.diseaseCISAIDiscontinuationProspective StudieAdverse eventsHIV-1Anti-Retroviral AgentCobicistatbusinesslcsh:RC581-607
researchProduct

Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA ≤50 cp/…

2017

Background: Nucleos(t)ide reverse transcriptase inhibitors (NRTI) toxicity may represent a threat for long-term success of combined antiretroviral therapy. Some studies have suggested a possible improvement of NRTI-related toxicity after switching to NRTI-sparing regimens. Objectives: We aimed to explore the efficacy and tolerability of switching to darunavir/ritonavir (DRV/r) plus raltegravir (RAL) while having a viral load (VL) ≤50 copies/mL in the clinical setting. Study design: Treatment-experienced HIV 1-infected patients enrolled in the ICONA Foundation Study cohort were included if they switched their current regimen to DRV/r + RAL with a HIV-RNA ≤50 copies/mL. Different defin…

0301 basic medicineMaleHIV InfectionsAntiretroviral therapy; Darunavir/ritonavir; Efficacy; NRTI-sparing regimen; Raltegravir; Tolerability; Microbiology (medical); Infectious DiseasesAntiretroviral therapy; Darunavir/ritonavir; Efficacy; NRTI-sparing regimen; Raltegravir; Tolerability; Adult; Anti-HIV Agents; Cohort Studies; Darunavir; Drug Therapy Combination; Female; HIV Infections; HIV-1; Humans; Italy; Male; Middle Aged; RNA Viral; Raltegravir Potassium; Ritonavir; Viral LoadGastroenterologyCohort StudiesAntiretroviral therapy; Darunavir/ritonavir; Efficacy; NRTI-sparing regimen; Raltegravir; Tolerability0302 clinical medicineMedicineNRTI-sparing regimen030212 general & internal medicineViralDarunavireducation.field_of_studyLamivudineGeneral MedicineMiddle AgedViral LoadTolerabilityAntiretroviral therapyInfectious DiseasesTolerabilityItalyCombinationRNA ViralDrug Therapy CombinationFemaleViral loadmedicine.drugAdultMicrobiology (medical)medicine.medical_specialtyEfficacyAnti-HIV Agents030106 microbiologyPopulationDarunavir/ritonavir; Raltegravir; Efficacy; Tolerability; Antiretroviral therapy; NRTI-sparing regimenSettore MED/17 - MALATTIE INFETTIVELower riskNO03 medical and health sciencesDrug TherapyInternal medicineRaltegravir PotassiumHumanseducationDarunavirRitonavirbusiness.industryDarunavir/ritonavirRaltegravirRaltegravirHIV-1RNARitonavirbusinessAntiretroviral therapy; Darunavir/ritonavir; Efficacy; NRTI-sparing regimen; Raltegravir; Tolerability;
researchProduct

Long-term efficacy and tolerability of intranasal fentanyl in the treatment of breakthrough cancer pain

2015

Purpose: The aim of the present study was to assess the long-term tolerability and efficacy of intranasal fentanyl (INFS) in opioid-tolerant patients with breakthrough cancer pain (BTP).Patients and methods: A 6 months, observational, prospective, cohort study design was employed to follow advanced cancer patients with BTP receiving INFS under routine clinical practice. Eligible adult cancer patients suffering from BTP had been prescribed INFS at effective doses. Data were collected at T0 and at month intervals for six months. The principal outcomes were the evaluation of possible serious adverse effects with prolonged use of INFS, the efficacy of BTP treatment with INFS, the quality of sle…

AdultMalemedicine.medical_specialtySettore MED/42 - Igiene Generale E ApplicataFentanylCohort StudiesPatient satisfactionNeoplasmsInternal medicineparasitic diseasesHumansPain ManagementMedicineProspective StudiesCancer painAdverse effectProspective cohort studyAdministration IntranasalAgedPain Measurementbusiness.industryBreakthrough PainMiddle AgedTolerabilityDiscontinuationAnalgesics OpioidFentanylBreakthrough pain; Cancer pain; Intranasal fentanyl; Tolerability; OncologyOncologyTolerabilityPatient SatisfactionAnesthesiaIntranasal fentanylFemaleSleepbusinessCancer painmedicine.drugCohort studySupportive Care in Cancer
researchProduct

Effects on executive functions of antiepileptic monotherapy in pediatric age.

2020

Abstract Objectives Cognitive abilities and executive functions in children and adolescents are important indicators of quality of life as well as academic and social achievements. Cognitive and executive functioning are often impaired in patients with epilepsy and can be exacerbated by seizures and antiseizure drugs. The aim of our observational retrospective study was to assess executive functioning in patients with pediatric epilepsy, currently taking a single antiseizure medication. Materials and methods Records of 172 children and adolescents aged between 6 and 18 years (mean age = 12 ± 3.4 years) with newly diagnosed epilepsy who had not yet commenced an antiepileptic treatment were i…

MalePediatricsmedicine.medical_specialtyLevetiracetamAdolescentAntiepileptic drugsOxcarbazepine03 medical and health sciencesBehavioral NeuroscienceEpilepsyExecutive Function0302 clinical medicinemedicineHumans030212 general & internal medicineOxcarbazepineChildChildrenRetrospective StudiesValproic AcidEpilepsybusiness.industrySeizure typesEpiTrack JuniorAge FactorsCarbamazepinemedicine.diseaseExecutive functionsTolerabilityCognitive functionsAntiepileptic drugs; Children; Cognitive functions; EpiTrack Junior; Executive function; TolerabilityCarbamazepineNeurologyTolerabilityQuality of LifeAnticonvulsantsFemaleCognitive functionNeurology (clinical)LevetiracetambusinessAntiepileptic drug030217 neurology & neurosurgerymedicine.drugEpilepsybehavior : EB
researchProduct

Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review

2017

Marco Solmi,1,2 Andrea Murru,3 Isabella Pacchiarotti,3 Juan Undurraga,4,5 Nicola Veronese,2,6 Michele Fornaro,7,8 Brendon Stubbs,2,9–11 Francesco Monaco,2 Eduard Vieta,3 Mary V Seeman,12 Christoph U Correll,13,14 André F Carvalho2,15 1Neuroscience Department, University of Padua, 2Institute for Clinical Research and Education in Medicine, Padua, Italy; 3Bipolar Disorders Unit, Institute of Neuroscience, Hospital Clínic, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain; 4Department of Psychiatry, Faculty of Medicine, Clínica Alemana Universidad del Desarrollo, 5Early Intervention Program, J. Horwitz Psychiatric Institute, Santiago, Chile; 6Na…

Olanzapinesafetymedicine.medical_specialtyside effectToxicology and Pharmaceutics (all)ReviewRM1-950psychosi03 medical and health sciencesIloperidonechemistry.chemical_compound0302 clinical medicineSertindoleJournal ArticlemedicineAsenapinePharmacology (medical)psychosisGeneral Pharmacology Toxicology and PharmaceuticstolerabilityPsychiatryLurasidoneBrexpiprazolePharmacologyChemical Health and Safetybusiness.industryMedicine (all)Transtornos PsicóticosGeneral Medicinepsychiatry3. Good health030227 psychiatryantipsychotics side effects tolerability safety psychosis psychiatryantipsychoticantipsychoticsside effectsPsychotic DisordersTolerabilitychemistryQuetiapineAntipsychotics; Psychiatry; Psychosis; Safety; Side effects; Tolerability; Medicine (all); Safety Research; Pharmacology Toxicology and Pharmaceutics (all); Chemical Health and Safety; Pharmacology (medical)Therapeutics. PharmacologyAntipsicóticosbusinessSafety Research030217 neurology & neurosurgeryAntipsychotic Agentsmedicine.drugTherapeutics and Clinical Risk Management
researchProduct

Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial

2014

BACKGROUND: In patients with relapsing-remitting MS (RRMS) fingolimod prevents disease relapses and delays disability progression. First dose administration of fingolimod is associated with a transient, dose-dependent decrease in heart rate (HR) in the 6 hours after drug intake.The aim of the study is to to assess safety and tolerability of the first dose of fingolimod in a cohort of Italian patients with RRMS without alternative therapeutic options. METHODS: Open-label, single arm, multicentre study. After the first dose of fingolimod, patients were observed for 6 hours and had their vital signs monitored hourly. Extended on-site monitoring was provided when required. RESULTS: Of the 906 p…

OncologyMaleNeurologyfingolimod multiple sclerosis treatment first dose safetyadministration /&/ dosage/adverse effects/analogs /&/ derivatives/therapeutic useImmunosuppressive AgentSphingosineMultiple SclerosiAtrioventricular Blockadministration /&/ dosage/adverse effects/therapeutic useGeneral MedicineMiddle AgedTolerabilityPropylene GlycolFingolimoddrug therapyTolerabilityAnesthesiaCohortAdolescent Adult Atrioventricular Block; chemically induced/epidemiology Drug Therapy; Combination Female Humans Immunosuppressive Agents; administration /&/ dosage/adverse effects/therapeutic use Male Middle Aged Multiple Sclerosis; drug therapy Propylene Glycols; administration /&/ dosage/adverse effects/therapeutic use Sphingosine; administration /&/ dosage/adverse effects/analogs /&/ derivatives/therapeutic use Young AdultCombinationDrug Therapy CombinationSettore MED/26 - NeurologiaFemaleAtrioventricular block; Bradycardia; Fingolimod; Multiple sclerosis; Safety; Tolerability; Adolescent; Adult; Atrioventricular Block; Drug Therapy Combination; Female; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Male; Middle Aged; Multiple Sclerosis; Propylene Glycols; Sphingosine; Young Adult; Neurology (clinical)SafetyAtrioventricular block Bradicardia Multiple sclerosis Fingolimod Safety TolerabilityImmunosuppressive AgentsResearch ArticleHumanmedicine.drugAdultmedicine.medical_specialtyMultiple SclerosisAdolescentClinical NeurologyYoung AdultFingolimod HydrochlorideInternal medicineBradycardiamedicineHumansNeurochemistryFingolimod Hydrochloridebusiness.industryMultiple sclerosisFingolimodmedicine.diseaseClinical trialPropylene GlycolsAtrioventricular block Bradycardia Multiple sclerosis Fingolimod Safety Tolerabilitychemically induced/epidemiologyNeurology (clinical)business
researchProduct

Potential tolerability of ancient grains in non-celiac wheat sensitivity patients: A preliminary evaluation

2022

Background and aimsA wheat-free diet (WFD) represents the elective treatment for Non-celiac Wheat Sensitivity (NCWS) patients. Preliminary reports have shown a possible better tolerability of ancient grains in these subjects. The aim of this observational study was to evaluate the frequency of consumption of ancient grains and its correlation with clinical manifestations in NCWS patients.Methods223 NCWS patients were recruited, and their consumption of ancient grains was monitored. Participants were first administered a modified version of the Pavia/Biagi questionnaire to investigate their adherence to “modern WFD.” The appearance/exacerbation of symptoms after ingestion of ancient grains w…

Settore MED/09 - Medicina InternaGeneral MedicineAmylase-Trypsin Inhibitors (ATIs) Non-celiac Wheat Sensitivity (NCWS) ancient grains wheat free diet wheat tolerabilityFrontiers in Medicine
researchProduct

A phase IB, multicenter, open-label study to assess the safety, tolerability, and efficacy of the pleiotropic pathway modifier CC122 administered ora…

2017

379 Background: CC122 is a novel cereblon-modulating agent with multiple biologic activities including potent immunomodulatory and antiangiogenic effects. CC-122 binding to cereblon promotes ubiquitination and subsequent degradation of lymphoid transcription factors Ikaros and Aiolos resulting in activation of T cells. Methods: Following establishment of oral CC122 3 mg daily (QD) as the MTD in phase 1a (Blood 122:2905 2013), an expansion cohort of advanced Hepatocellular Carcinoma (HCC) subjects was enrolled. All subjects had progressed on or were intolerant to sorafenib. Efficacy was assessed per RECIST 1.1 criteria. Results: As of Jan. 13, 2016, 25 advanced HCC subjects were enrolled. T…

SorafenibOncologyCancer Researchmedicine.medical_specialtybusiness.industryCereblonSafety tolerabilityPharmacologymedicine.diseaseOncologyOpen label studyInternal medicineHepatocellular carcinomaCohortmedicinebusinessmedicine.drugJournal of Clinical Oncology
researchProduct

Efficacy, safety and tolerability of aripiprazole in bipolar disorder: An updated systematic review and meta-analysis of randomized controlled trials

2017

Numerous studies have investigated aripiprazole as a treatment for bipolar disorder (BD). therefore we conducted this comprehensive meta-analysis to investigate the efficacy and safety profile of aripiprazole in treating BD. Two authors conducted systematic searches of PubMed and ScienceDirect from inception until May 14th, 2017. Randomized controlled trials (RCTs) of people with BD who received aripiprazole were included. A total of 20 RCTs met the eligibility criteria, including two which investigated the efficacy of aripiprazole versus haloperidol (aripiprazole = 340; haloperidol = 337), three which compared aripiprazole versus lithium (aripiprazole = 208; lithium = 212), and 15 with mul…

Transtorno Bipolarmedicine.medical_specialtyEfficacyBipolar disorderAripiprazolePlacebolaw.invention03 medical and health sciences0302 clinical medicineMaintenance therapyRandomized controlled trialAripiprazole; Bipolar disorder; Efficacy; Meta-analysis; Tolerability; Pharmacology; Biological PsychiatrylawInternal medicinemedicineHaloperidolHumansMeta-analysiBipolar disorderPsychiatryBiological PsychiatryRandomized Controlled Trials as TopicAripiprazole Bipolar disorder Efficacy Tolerability Meta-analysisPharmacologymedicine.diseaseTolerability030227 psychiatryMeta-analysisAripiprazolTolerabilityMeta-analysisAripiprazolePsychology030217 neurology & neurosurgeryAntipsychotic Agentsmedicine.drug
researchProduct

Perampanel and Visuospatial Skills in Children With Epilepsy

2021

Introduction: Perampanel (PER) is a non-competitive AMPA glutamate receptor antagonist approved for focal and generalized seizures as add-on therapy. PER does not seem to negatively affect the cognitive profile in children and adolescents, but its influence on visuospatial abilities is still to be assessed. The aim of our study was to assess visuospatial skills through a standardized neuropsychological evaluation in adolescents taking PER for 12 months.Methods: Our sample included 46 adolescents aged 12–18 years with focal and generalized drug-resistant epilepsy already in therapy with one or two antiseizure medications. Changes in visuospatial perception and memory were assessed by the Rey…

medicine.medical_specialtygenetic structuresAudiologybehavioral disciplines and activitiesSpatial memory050105 experimental psychology03 medical and health sciencesPerampanelchemistry.chemical_compound0302 clinical medicineperampanelchildrenmedicineadverse effects children perampanel tolerability visuospatial memory0501 psychology and cognitive sciencesGlutamate receptor antagonisttolerabilityRC346-429Original Researchbusiness.industry05 social sciencesNeuropsychologyCognitionExecutive functionsNeurologychemistryVisuospatial perceptionAdjunctive treatmentadverse effectsvisuospatial memoryNeurology. Diseases of the nervous systemNeurology (clinical)business030217 neurology & neurosurgery
researchProduct